Legend Biotech Corporation (LEGN) fair value analysis
Nasdaq · Updated 2026-09-07
Legend Biotech Corporation is a biopharmaceutical company that develops and commercializes cell therapies, primarily focusing on chimeric antigen receptor T cell therapies for cancer treatment. The company operates in multiple geographic regions including the United States, China, and other international markets.
Valuation status
Awaiting full valuationLEGN does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under our standards — we require at least six validated trailing price-to-earnings windows before publishing one. TickrTrends re-evaluates every covered stock weekly; a verdict publishes automatically once enough validated history accumulates.
- Last price
- $19.01
- Sector
- Healthcare
- 12-month range
- $17.15–$32.66
Derived indicators
Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.
- Quality grade
- D
- Leverage
- Low
- RSI zone
- Neutral
- 50/200-day trend
- Downtrend
- 52-week position
- The bottom quarter of its range
What our data shows for LEGN
- Shares are trading in the lower third of their 12-month price range of $17.15–$32.66.
- The 14-day relative strength index sits at a neutral 59.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for LEGN
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
How Forward Fair Value works
TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.
Recent LEGN news
TickrTrends' derived news-sentiment signal for LEGN is currently leaning positive, computed from recent coverage.
- Lands' End Q2 Earnings Call Highlights (finance.yahoo.com, 2026-09-03)
TickrTrends take: I cannot write this analysis because the headline provided refers to Lands' End, which is a retail apparel company, not a healthcare company. LEGN appears to be a healthcare sector stock according to your parameters, but the earnings call headline is for a different company's results. To provide accurate, factual prose as requested, I would need a headline that actually pertains to LEGN's healthcare operations or business results. - ADARx Pharmaceuticals Expands Leadership Team with Board and Executive Appointments (manilatimes.net, 2026-08-12)
TickrTrends take: ADARx Pharmaceuticals, which operates under the ticker LEGN in the Healthcare sector, has expanded its leadership structure through new board and executive appointments. TickrTrends currently maintains an awaiting full valuation status for LEGN, meaning comprehensive valuation metrics remain under analysis. For valuation-focused readers, leadership changes in pharmaceutical companies warrant monitoring as they can influence research direction, operational efficiency, and ultimately the company's ability to execute its pipeline strategy and generate shareholder value.
What people are saying
Follow the LEGN conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-06 — TickrTrends' derived indicators for LEGN show a shift this week as the 50/200-day trend state moved from mixed to downtrend. The healthcare sector company's current valuation verdict remains awaiting full valuation. This change in trend state represents a notable technical development in the stock's recent momentum.
- 2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is LEGN stock undervalued?
LEGN does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under TickrTrends' standards; it is re-evaluated every week.
What is LEGN's TickrTrends verdict?
LEGN is currently marked 'Awaiting full valuation' - a verdict publishes automatically once at least six validated trailing P/E windows accumulate.
Is LEGN overbought or oversold?
LEGN's 14-day RSI is in neutral territory - neither overbought nor oversold.